Approach to intrapartum fever during the COVID-19 pandemic: A New York City Hospital experience - 19/06/24
, Julia Cron, MD b, Szilvia Nagy, MD b, Lisa Saiman, MD, MPH c, Harjot K. Singh, MD, SCM dRésumé |
The yield of repeat severe acute respiratory syndrome coronovirus 2 (SARS-CoV-2) testing for intrapartum fever in patients admitted to labor and delivery negative for SARS-CoV-2 on admission testing is unknown. From October 2020 to June 2022, we performed a retrospective study of 151/3,168 (4.8%) patients who had repeat testing for intrapartum fever. One (0.7%) patient was SARS-CoV-2-positive suggesting repeat SARS-CoV-2 testing for intrapartum fever is generally not warranted nor is separating birthing dyads while awaiting test results.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Highlights |
• | The yield of repeat SARS-CoV-2 testing for intrapartum fever is low. |
• | Repeat respiratory pathogen testing for intrapartum fever is not warranted. |
• | Isolation and separation of birthing dyads for intrapartum fever are not necessary. |
• | Infection prevention policies specific to the pregnant population are essential. |
Key Words : SARS-CoV-2 testing, Infection prevention and control, Birthing dyad separation
Plan
| Conflicts of interest: Conflicts of interest for Lisa Saiman are as follows: Grant support from Merck Co., Inc, Consulting fees for the Cystic Fibrosis Foundation, and Participation on a Data safety monitoring board or advisory board for Merck Co., Inc and Pfizer, Inc. All other authors with no conflicts of interest disclosed. |
Vol 52 - N° 7
P. 860-862 - juillet 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
